Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Sponsor: Arcturus Therapeutics, Inc.
Summary
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Official title: A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-12-12
Completion Date
2025-12
Last Updated
2025-10-09
Healthy Volunteers
No
Conditions
Interventions
ARCT-032
CFTR mRNA formulated in lipid nanoparticles
Locations (11)
University of Arizona
Tucson, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Children's Hospital of Los Angeles
Los Angeles, California, United States
Joe DiMaggio Children's Hospital
Hollywood, Florida, United States
Central Florida Pulmonary Group
Orlando, Florida, United States
The Cystic Fibrosis Institute
Northfield, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Washington University
St Louis, Missouri, United States
Vanderbilt University
Nashville, Tennessee, United States
UT Health
San Antonio, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States